Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 73.03 USD 0.4%
Market Cap: 11.6B USD
Have any thoughts about
Bio-Techne Corp?
Write Note

Net Margin
Bio-Techne Corp

13.9%
Current
21%
Average
0.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
13.9%
=
Net Income
201.7m
/
Revenue
1.4B

Net Margin Across Competitors

Country US
Market Cap 11.6B USD
Net Margin
14%
Country US
Market Cap 1.2T USD
Net Margin
9%
Country US
Market Cap 202.3B USD
Net Margin
14%
Country US
Market Cap 166.6B USD
Net Margin
18%
Country KR
Market Cap 66.8T KRW
Net Margin
24%
Country CH
Market Cap 38.4B CHF
Net Margin
9%
Country US
Market Cap 38.8B USD
Net Margin
20%
Country US
Market Cap 36.3B USD
Net Margin
9%
Country US
Market Cap 27B USD
Net Margin
21%
Country US
Market Cap 24.1B USD
Net Margin
17%
Country CN
Market Cap 162B CNY
Net Margin
21%
No Stocks Found

Bio-Techne Corp
Glance View

Market Cap
11.6B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.

TECH Intrinsic Value
57.79 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
13.9%
=
Net Income
201.7m
/
Revenue
1.4B
What is the Net Margin of Bio-Techne Corp?

Based on Bio-Techne Corp's most recent financial statements, the company has Net Margin of 13.9%.